Welcome to our dedicated page for Biovie SEC filings (Ticker: BIVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioVie Inc. (NASDAQ: BIVI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed biopharmaceutical issuer, BioVie files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements on Schedule 14A, and registration statements such as Form S-1 related to securities offerings.
Through these filings, BioVie describes its clinical-stage programs in neurological and neurodegenerative disorders and advanced liver disease, including development of bezisterim (NE3107) for Alzheimer’s disease, Parkinson’s disease and long COVID, and BIV201, a continuous infusion terlipressin therapy for complications of advanced liver cirrhosis. Investors can review risk factors, clinical trial descriptions, regulatory designations such as Orphan Drug and Fast Track status for BIV201, and discussions of how neuroinflammation and insulin resistance are believed to relate to the company’s target indications.
Current reports on Form 8-K capture material events such as underwritten public offerings of units and warrants, the listing of warrants under the symbol BIVIW, the implementation of a one-for-ten reverse stock split, amendments to the 2019 Omnibus Equity Incentive Plan, and changes in the composition of the board of directors. Registration statements and their amendments detail the terms of securities being offered, including units, pre-funded warrants, and warrants, and provide additional narrative on BioVie’s business and clinical pipeline.
On Stock Titan, these SEC documents are presented with real-time updates from EDGAR and AI-powered summaries that help explain the key points of lengthy filings. Users can quickly identify items related to clinical trial progress, capital raising transactions, equity incentive plans, and corporate governance without reading every page. Forms 10-K and 10-Q can be reviewed with AI-generated highlights of segment information and risk disclosures, while Form 4 and related ownership filings, when available, can be used to monitor insider equity activity.
This centralized view of BioVie’s SEC filings allows investors and researchers to track how the company describes its neurology and liver disease programs, financing activities, and corporate actions over time, with AI tools to make complex regulatory language more accessible.
BioVie Inc. reported that stockholders approved an amendment and restatement of its 2019 Omnibus Equity Incentive Plan, effective November 10, 2025. The revised plan increases the number of shares of common stock authorized for issuance under the plan to 3,100,000 shares.
The plan is intended to help attract, retain, and incentivize employees, directors, and consultants, and to align their interests with stockholders. The full amended plan is incorporated by reference from the company’s September 25, 2025 definitive proxy statement.
BioVie Inc. reported results from its 2025 annual meeting of stockholders. On the September 22, 2025 record date, 7,535,080 shares were outstanding, and 3,417,857 shares were present for quorum. Stockholders elected all six director nominees to one‑year terms; each nominee received over 1.51 million "For" votes, with 1,864,509 broker non‑votes recorded on each director item.
Stockholders ratified EisnerAmper LLP as independent auditor for the fiscal year ending June 30, 2026 with 3,245,049 For, 141,868 Against, and 30,940 Abstain. They also approved an amendment and restatement of the 2019 Omnibus Equity Incentive Plan to increase the number of shares authorized for issuance to 3,100,000 (votes: 1,340,062 For, 207,794 Against, 5,492 Abstain, and 1,864,509 broker non‑votes).
BioVie Inc. filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $5.1 million, driven by operating expenses of $5.3 million (R&D $2.9 million; G&A $2.3 million). Other income, net, was $0.2 million mainly from interest income.
Cash and cash equivalents rose to $25.0 million from $17.5 million at June 30, 2025, supported by net proceeds of approximately $10.5 million from an August 2025 underwritten offering of units and pre-funded units, each including warrants exercisable at $2.50. Net cash used in operations was $3.0 million.
The company advanced its clinical programs: a Phase 2b study in Parkinson’s disease commenced in April 2025, and the DOD-funded Long COVID Phase 2 study continued, with $336,000 in grant reimbursements recognized this quarter. BioVie disclosed “substantial doubt” about its ability to continue as a going concern, noting dependence on additional financing. A 1-for-10 reverse stock split became effective July 7, 2025. Shares outstanding were 7,540,316 as of November 7, 2025.
BioVie Inc. (BIVI) filed a Form 3, the initial statement of beneficial ownership for a board member. The reporting person is a Director, and the filing states that no securities are beneficially owned as of the event date 07/17/2025. The form indicates it was filed by one reporting person. This is a routine ownership disclosure that establishes the insider’s baseline holdings at the time of becoming subject to reporting.
BioVie Inc. (BIVI) disclosed a Form 3 filed by a director, indicating no securities are beneficially owned by the reporting person. The filing identifies the relationship as Director and notes the event date as 07/17/2025. The form was filed by one reporting person.
BioVie Inc. filed a post-effective amendment to its Form S-1 registration statement, acting as an exhibits-only update. The amendment’s sole purpose is to add the consent of EisnerAmper LLP as the company’s independent registered public accounting firm, covering its report dated August 15, 2025 on BioVie’s financial statements for the year ended June 30, 2025. The consent is filed as Exhibit 23.1, and the rest of the prospectus and Part II of the registration statement remain unchanged.
BioVie Inc. solicits shareholder votes at its virtual annual meeting and presents director nominees, auditor ratification and an amendment to increase shares available under its 2019 equity plan to 3,100,000 shares. The proxy names the board slate including Cuong Do (President & CEO) and committee chairs for audit, compensation and governance. Compensation tables show named executive officer pay components: for example, the CEO's total compensation entries include cash and equity components (reported totals such as $777,082 for one year and $420,621 for another row). Director and NEO equity holdings and outstanding option/RSU schedules are disclosed, including a listed beneficial ownership aggregate of 65,312 shares (0.9%) for listed insiders. Audit fees paid to the auditor are disclosed (audit-related fees shown as $99,750 and tax fees $26,250).
BioVie, Inc. (BIVI) is a development-stage biopharmaceutical company with no products approved for commercial sale and no revenues expected in the foreseeable future. The company reported approximately $17.5 million in cash and cash equivalents, stockholders' equity of about $19.0 million, and an accumulated deficit of approximately $352.1 million. For the year, reported net losses included $(17,911,585) and $(33,006,956) as referenced in the statements, with net loss per common share of $(12.12) for the most recent period on a weighted average of 1,477,372 shares. BioVie continues preclinical and clinical development activities, holds multiple issued and pending patents and patent applications, and lists significant operational risks including dependence on third-party contractors, need for additional capital, litigation, manufacturing and regulatory hurdles, and potential volatility and dilution from equity financings. Recent equity raises and warrant offerings are described, and management discloses lease, debt, and fair-value measurement items that affected financing costs and interest expense.
Cuong V Do, President & CEO and director of BioVie, purchased securities in the company's public offering. On 08/07/2025 he acquired 5,000 shares of common stock and received accompanying warrants covering 5,000 shares; the combined purchase price per share and warrant was $2.00 in connection with the offering that closed on 08/11/2025.
After the reported transactions the filing shows the reporting person beneficially owning 9,992 common shares and 5,050 warrants indirectly. The securities are held in the name of Do & Rickles Investments LLC.